Posts by: Steve Bryson PhD

Steve Bryson PhD

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.

March 22, 2021March 22, 2021

Switch to Rixubis Not Linked to Increased Bleed Rates in Small Study

News

For people with hemophilia B, switching to Rixubis (nonacog gamma) as a factor IX (FIX) replacement therapy was not associated with increased bleeding rates, dose changes, adverse blood clotting events, or the development ... Read more

January 29, 2021January 29, 2021

Esperoct Highly Effective as Prophylaxis for Hemophilia A, Study Suggests

News

Severe hemophilia A patients using Esperoct (turoctocog alfa pegol) as a preventive treatment do well, with fewer bleeds or breakthrough bleeds, lower costs, and better life quality compared with other ... Read more

November 30, 2020November 30, 2020

Most Hemophilia Patients Show Positive Attitude for Gene Therapy in Study

News

Most people with hemophilia have a positive attitude toward gene therapy, and are willing or “very willing” to receive this treatment, according to a small interview study assessing patient perceptions. ... Read more

November 23, 2020November 23, 2020

Insurance Firm BCS Partners With NHF to Improve Healthcare Quality, Cost

News

The healthcare insurance company BCS Financial has partnered with the National Hemophilia Foundation (NHF) to improve care quality and cost for people with hemophilia. BCS Financial provides services primarily for Blue ... Read more

September 23, 2020September 23, 2020

GC Pharma, Atomwise Aim for Potential Oral Hemophilia Therapies

News

Atomwise, a company that specializes in using artificial intelligence (AI) to develop small molecule medicines, will partner with GC Pharma to discover new ways of treating people with hemophilia. The partnership ... Read more

July 27, 2020July 27, 2020

#ISTH2020 – Unmet Medical Need Found in Mild, Moderate Hemophilia A Care

News

Adults with mild and moderate hemophilia A have a substantial number of bleeds per year as well as joint problems and surgeries, revealing an unmet medical need in these patients, ... Read more

July 6, 2020July 6, 2020

Idelvion Approved in Europe for 21-day Prophylactic Dosing in Adults With Hemophilia B

News

The European Medicines Agency (EMA) has approved 21-day dosing intervals for CSL Behring‘s Idelvion (rIX‐FP) as a prophylactic treatment for adults with hemophilia B. Idelvion — which is also approved ... Read more

June 10, 2020June 10, 2020

Sernova Testing AgeX’s UniverCyte Technology to Deliver FVIII to Hemophilia A Patients

News

Sernova will use AgeX Therapeutics’ UniverCyte gene technology to create a cell-based therapy that delivers therapeutic levels of factor VIII (FVIII) — the blood clotting protein deficient in people with hemophilia ... Read more

June 5, 2020June 5, 2020

Gene, Cell Therapy Combo Shows Promise for Treating Hemophilia A, Study Reports

News

A new combination of gene and cell-based therapy durably delivered therapeutic levels of factor VIII (FVIII) — the blood clotting protein missing or defective in people with hemophilia A — ... Read more

June 1, 2020June 1, 2020

RNA Gene Therapy Seen to Effectively Treat Hemophilia A Mouse Model

News

A new type of gene therapy that uses RNA instead of DNA led to rapid and prolonged production of therapeutic levels of factor VIII (FVIII) in a mouse model of ... Read more